Last week’s deal-making news included US biotech Alumis signing a licensing agreement with Japan’s Kaken Pharma for its ...

US gene therapy company bluebird bio (Nasdaq: BLUE) has confirmed receipt of an unsolicited non-binding written proposal from ...

The interleukin-2 (IL-2) therapies market in the USA is poised for major growth, projected to reach $4 billion by 2034, ...

The European Medicines Agency’s (EMA’) human medicines committee (CHMP) has recommended two new medicines and three ...

German life sciences and pharma company Merck KGaA (MRK: DE) today revealed it has exercised its option with China’s Abbisko ...

US genomics firm Galatea Bio has raised $25 million in funding to expand its global biobank and accelerate the development of ...

Italian biopharma Chiesi Group has announced a major investment in Nerviano, near Milan, with the building of a new facility ...

Polygenic diseases company Character Biosciences has announced an oversubscribed $93 million Series B financing round to ...

US pharma major Merck & Co (NYSE: MRK) has shared the first results from a late-stage trial of a subcutaneous version of its ...

Singaporean biotech Shanton Pharma has reported positive top-line results from a Phase IIb clinical trial of its ...

Cardiovascular-focused Milestone Pharmaceuticals was trading more than 60% lower early in trading on Friday, with its share ...

Japan’s Ministry of Health, Labor and Welfare in Japan has granted marketing and manufacturing authorization for Dupixent ...